KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Receivables (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Change in Receivables for 5 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 17483.61% year-over-year to $10.7 million, compared with a TTM value of $4.9 million through Dec 2025, down 60.58%, and an annual FY2025 reading of $4.9 million, down 60.58% over the prior year.
  • Change in Receivables was $10.7 million for Q4 2025 at Aurinia Pharmaceuticals, up from -$9.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $23.6 million in Q3 2022 and bottomed at -$28.3 million in Q4 2022.
  • Average Change in Receivables over 5 years is $2.1 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 841.14% in 2024, then skyrocketed 17483.61% in 2025.
  • Year by year, Change in Receivables stood at $5.6 million in 2021, then tumbled by 605.05% to -$28.3 million in 2022, then surged by 51.01% to -$13.9 million in 2023, then soared by 100.44% to $61000.0 in 2024, then surged by 17483.61% to $10.7 million in 2025.
  • Business Quant data shows Change in Receivables for AUPH at $10.7 million in Q4 2025, -$9.4 million in Q3 2025, and -$259000.0 in Q2 2025.